INVESTIGATION OF CLINICAL AND HORMONAL EFFECTS OF GHRP, GHRH, AND 1485 PLUS GHRH

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。研究表明，GHRH对身材矮小儿童的生长速度和GH水平具有持续的积极作用，并且即使在停止GHRH后也表现出延长的效果，这表明GHRH可能恢复GH分泌。其他涉及老年男性长期服用GHRH 14天的研究表明，GHRH可以逆转GH和IGF水平的下降。已经开发了几种称为生长激素释放肽的合成肽。已经发现GHRPs在多种动物中释放GH。GHRP通过对下丘脑和垂体的作用通过非阿片类、非GHRH受体特异性地释放GH。据推测，GHRP的活性反映了特定内源性激素和受体的活性。当与GHRH结合使用时，GHRP非常协同地释放GH。GHRP-1已在正常男性和女性中进行了测试，没有发现实验室或临床不良反应。GHRP-2现在已经长期给予正常的年轻男女，老年人，儿童和垂体瘤患者。在这项研究中，剂量反应效应iv，sc，和口服的1485，另一种GHRP，将单独研究和与GHRH的组合，以测量疗效和安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies have shown the sustained positive effect of GHRH on growth rate and GH levels in short stature children and demonstrated a prolonged effect even after discontinuing GHRH which indicates it may be possible to restore GH secretion with GHRH. Other studies involving chronic administration of GHRH for fourteen days in elderly men showed that GHRH can reverse decreased GH and IGF levels. Several synthetic peptides, called Growth Hormone Releasing Peptides, have been developed. GHRPs have been found to release GH in a variety of animals. GHRP specifically releases GH by an action on the hypothalamus and pituitary via non-opiate, non-GHRH receptors. It is hypothesized that the activity of GHRP reflects the activity of a specific endogenous hormone and receptor. When used in combination with GHRH, GHRP very synergistically releases GH. GHRP-1 has been tested in normal men and women and revealed no laboratory or clinical adverse effects. GHRP-2 has now been given chronically to normal young men and women, elderly subjects, children and patients with pituitary tumors. In this study, the dose response effect iv, sc, and orally of 1485, another GHRP, will be studied alone and in combination with GHRH to measure efficacy and safety.